148 related articles for article (PubMed ID: 38334382)
1. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update.
Roccuzzo G; Bongiovanni E; Tonella L; Pala V; Marchisio S; Ricci A; Senetta R; Bertero L; Ribero S; Berrino E; Marchiò C; Sapino A; Quaglino P; Cassoni P
Expert Rev Mol Diagn; 2024; 24(1-2):49-66. PubMed ID: 38334382
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive biomarkers in melanoma.
Maher NG; Vergara IA; Long GV; Scolyer RA
Pathology; 2024 Mar; 56(2):259-273. PubMed ID: 38245478
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in melanoma.
Griewank KG
Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
[TBL] [Abstract][Full Text] [Related]
6. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios.
Roccuzzo G; Sarda C; Pala V; Ribero S; Quaglino P
Expert Rev Mol Diagn; 2024 May; ():1-14. PubMed ID: 38738539
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma.
De Falco V; Napolitano S; Esposito D; Guerrera LP; Ciardiello D; Formisano L; Troiani T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503876
[TBL] [Abstract][Full Text] [Related]
8. Prognostic biomarkers of cutaneous melanoma.
Ding L; Gosh A; Lee DJ; Emri G; Huss WJ; Bogner PN; Paragh G
Photodermatol Photoimmunol Photomed; 2022 Sep; 38(5):418-434. PubMed ID: 34981569
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review.
Cornelius LA; Fields RC; Tarhini A
Oncologist; 2021 Sep; 26(9):e1644-e1651. PubMed ID: 34080754
[TBL] [Abstract][Full Text] [Related]
10. Current status of diagnostic and prognostic markers in melanoma.
Levine D; Fisher DE
Methods Mol Biol; 2014; 1102():177-97. PubMed ID: 24258980
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
12. Melanoma biomarkers: current status and vision for the future.
Larson AR; Konat E; Alani RM
Nat Clin Pract Oncol; 2009 Feb; 6(2):105-17. PubMed ID: 19107110
[TBL] [Abstract][Full Text] [Related]
13. Relevance of BRAF Subcellular Localization and Its Interaction with
Beleaua MA; Jung I; Braicu C; Milutin D; Gurzu S
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769348
[TBL] [Abstract][Full Text] [Related]
14. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
15. Emerging Biomarkers in Cutaneous Melanoma.
Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
Huang SK; Hoon DS
Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.
Shah KP; Song H; Ye F; Johnson DB
Oncologist; 2021 Feb; 26(2):e333-e335. PubMed ID: 33044751
[TBL] [Abstract][Full Text] [Related]
18. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.
Jovanovic B; Kröckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
J Invest Dermatol; 2008 Nov; 128(11):2696-2704. PubMed ID: 18509361
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological relevance of BRAF mutations in human cancer.
Pakneshan S; Salajegheh A; Smith RA; Lam AK
Pathology; 2013 Jun; 45(4):346-56. PubMed ID: 23594689
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients.
Li X; Cai Y
Aging (Albany NY); 2020 Aug; 12(16):16457-16475. PubMed ID: 32858528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
